Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib | BIOLOGICAL | - |
Inclusion criteria * Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol. * A male or female of at least 15 months of age at the time of the booster vaccination, who had previously received 3-dose primary vaccination and, if ...
Top 20 of 23 competitors
Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib is a combination vaccine formulation studied for protection against Hib disease along with diphtheria, tetanus, pertussis, and hepatitis B. It is being developed by GSK plc as a pediatric vaccine candidate intended for prophylactic immunization in young children.
GSK plc, which trades under the ticker GSK, is the developer of the Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib vaccine formulation. The company sponsored the clinical trial evaluating this combination vaccine candidate.
Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib is in Phase 2 development. It is an investigational combination vaccine candidate and is not described as approved. The Phase 2 trial evaluating this formulation has been completed.
Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib was evaluated in one completed Phase 2 trial, NCT00158808. The study enrolled 175 healthy volunteers aged 15 months and older in the Philippines and assessed immune memory and reactogenicity of a booster dose given at 15 to 18 months.
The Phase 2 trial NCT00158808 was a randomized study with 175 healthy volunteers aged 15 months and older in the Philippines. It was an uncontrolled trial, meaning it did not use a comparator control arm, and it evaluated a booster dose administered at 15 to 18 months of age.